Genopathy
Gene-Disorder Association · Article
Gene
KRAS
KRAS Proto-Oncogene, GTPase
Approved treatment annotated
Association Review

In brief

The association between KRAS (KRAS Proto-Oncogene, GTPase) and Chronic Myelogenous Leukemia, Bcr-Abl1 Positive is supported by expert-curated evidence, drawing on a single expert-curated source, which records pathogenic variants.

Sources 1
Clinical variants 1
Symptoms 0
Compounds 3
Trials 228of 871 via KRAS compounds
Publications 0
01
At a glance

Association overview

A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.

Request access
02
Provenance

Evidence and sources

1 source

Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.

Request access
03
KRAS

The gene

2 source summaries

A gene summary alongside the source descriptions it was distilled from.

Request access
04
Chronic Myelogenous Leukemia, Bcr-Abl1 Positive

The disorder

5 database identifiers

The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).

Request access
05
ClinVar and variant evidence

Genetic basis

1 clinical variant

ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.

Request access
06
Interventions

Therapeutics

3 compounds & drugs

Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.

Request access
07
Human studies

Clinical trials

871 clinical trials

Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.

Request access
08
Provenance

References & sources

5 references

Every source and publication cited across this dossier, as one numbered reference list.

Request access